Skip to Content
Merck

E8656

Heat-Labile Enterotoxin, B subunit (LTB)

from E. coli, >90% (SDS-PAGE), immunogen, lyophilized powder

Synonym(s):

LTB

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

UNSPSC Code:
12352200
NACRES:
NA.77
Assay:
>90% (SDS-PAGE)
Form:
lyophilized powder
Quality level:
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


Product Name

Heat-Labile Enterotoxin, B subunit (LTB) from E. coli, recombinant, expressed in Pichia pastoris, >90% (SDS-PAGE), lyophilized powder

recombinant

expressed in Pichia pastoris

Quality Level

assay

>90% (SDS-PAGE)

form

lyophilized powder

shipped in

wet ice

storage temp.

2-8°C

Application

Heat-Labile Enterotoxin, B subunit (LTB) from E. coli has been used in enzyme-linked immunosorbent assay (ELISA).

Biochem/physiol Actions

Enterotoxigenic Escherichia coli causes diarrhea through its heat-labile enterotoxin (LT). The LT is a periplasmic protein composed of one A subunit (LTA, 27 kDa) and five non-covalently associated B subunits (LTB, 11.6 kDa each) forming a ring-like pentamer. LTB has high affinity towards the toxin receptor ganglioside GM1, a glycosphingolipid found ubiquitously on the surface of mammalian cells. Ganglioside GM1 facilitates the delivery of the A subunit to the cytosol of the target cell resulting in persistent synthesis of cAMP and subsequently diarrhea. This characteristic makes LTB a good label for microglial cells (due to the enrichment of ganglioside GM1 on their cell surface). In addition, studies made mostly with animal models demonstrated that recombinant LTB could stimulate strong serum and mucosal immune responses against LT. Other studies have indicated that LTB could be used as a potent mucosal adjuvant.
Heat-Labile Enterotoxin, B subunit (LTB) is a good label for microglial cells. In addition, recombinant LTB stimulates strong serum and mucosal immune responses against heat-labile enterotoxin (LT). Other studies have indicated that LTB could be used as a potent mucosal adjuvant.

Features and Benefits

This compound is a featured product for Cyclic Nucleotide research. Click here to discover more featured Cyclic Nucleotide products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

Physical form

Lyophilized from a solution containing Heat-Labile Enterotoxin, B subunit in 0.05 M Tris buffer, pH 7.5, 0.2 M NaCl, 3 mM NaN3, and 1 mM sodium EDTA.

Analysis Note

The activity is measured by ELISA using ganglioside GM1-coated plates (Cat. No. G7641). LTB at various concentrations is incubated on the ganglioside GM1 coated wells, followed by anti-cholera toxin antibody (Cat. No. C3062), and peroxidase-labeled goat anti-rabbit IgG (Cat.No. A0545) as the secondary antibody. Binding saturation of 50% may be achieved with = 0.12 μg/mL of LTB.


pictograms

Exclamation mark

signalword

Warning

hcodes

Hazard Classifications

Acute Tox. 4 Dermal - Aquatic Chronic 3

Storage Class

11 - Combustible Solids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Faceshields, Gloves, type ABEK (EN14387) respirator filter



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library


Related Content

Instructions


Safety and immunogenicity of escalating dosages of a single oral administration of peru-15 pCTB, a candidate live, attenuated vaccine against enterotoxigenic Escherichia coli and Vibrio cholerae
Chen WH, et al.
Clinical and Vaccine Immunology : CVI, 22(1) (2015)
Preformulation Characterization and Stability Assessments of Secretory IgA Monoclonal Antibodies as Potential Candidates for Passive Immunization by Oral Administration
Hu Y, et al.
Journal of Pharmaceutical Sciences, 109(1) (2020)
Sandra Scheiblhofer et al.
Vaccine, 39(32), 4399-4403 (2021-07-07)
The skin represents an attractive target tissue for vaccination against respiratory viruses such as SARS-CoV-2. Laser-facilitated epicutaneous immunization (EPI) has been established as a novel technology to overcome the skin barrier, which combines efficient delivery via micropores with an inherent



Global Trade Item Number

SKUGTIN
E8656-0.5MG04061833608821